These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10219970)

  • 21. Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats.
    Brunner V; Maynadier B; Chen L; Roques L; Hude I; Séguier S; Barthe L; Hermann P
    Drug Des Devel Ther; 2015; 9():3199-215. PubMed ID: 26150694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Orally-dissolving film for sublingual and buccal delivery of ropinirole.
    Lai KL; Fang Y; Han H; Li Q; Zhang S; Li HY; Chow SF; Lam TN; Lee WYT
    Colloids Surf B Biointerfaces; 2018 Mar; 163():9-18. PubMed ID: 29268211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The disposition of gemifloxacin, a new fluoroquinolone antibiotic, in rats and dogs.
    Ramji JV; Austin NE; Boyle GW; Chalker MH; Duncan G; Fairless AJ; Hollis FJ; McDonnell DF; Musick TJ; Shardlow PC
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):435-42. PubMed ID: 11259328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys.
    Fukuzaki K; Kamenosono T; Nagata R
    Pharmacol Biochem Behav; 2000 Mar; 65(3):503-8. PubMed ID: 10683491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys.
    Radulovic LL; Türck D; von Hodenberg A; Vollmer KO; McNally WP; DeHart PD; Hanson BJ; Bockbrader HN; Chang T
    Drug Metab Dispos; 1995 Apr; 23(4):441-8. PubMed ID: 7600909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey.
    Tse FL; Smith HT; Ballard FH; Nicoletti J
    Biopharm Drug Dispos; 1990; 11(6):519-31. PubMed ID: 2207302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and first clinical experiences with an antihypertensive dopamine (DA2) agonist.
    Meyer W; Bühring KU; Steiner K; Ungethüm W; Schnurr E
    Eur Heart J; 1992 Sep; 13 Suppl D():121-8. PubMed ID: 1356782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling.
    Feng MR; Loo J; Wright J
    Drug Metab Dispos; 1998 Oct; 26(10):982-8. PubMed ID: 9763403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition of [14C]avitriptan in rats and humans.
    Marathe PH; Greene DS; Barbhaiya RH
    Drug Metab Dispos; 1997 Jul; 25(7):881-8. PubMed ID: 9224783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and disposition of lidamidine hydrochloride (WHR-1142A), a novel antidiarrheal agent, in rat and monkey.
    DeLong AF; Martin GP; Polk A; Carter V; Herczeg T
    Arzneimittelforschung; 1978; 28(8a):1477-80. PubMed ID: 113016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review.
    Setnikar I; Rovati LC
    Arzneimittelforschung; 2001 Sep; 51(9):699-725. PubMed ID: 11642003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disposition of 14C-loprazolam in animals and man.
    Illing HP; Ings RM; Johnson KI; Fromson JM
    Xenobiotica; 1983 Jul; 13(7):439-49. PubMed ID: 6140793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ropinirole in the treatment of restless legs syndrome.
    Kakar RS; Kushida CA
    Expert Rev Neurother; 2005 Jan; 5(1):35-42. PubMed ID: 15853472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man.
    Grindel JM; O'Neill PJ; Yorgey KA; Schwartz MH; McKown LA; Migdalof BH; Wu WN
    Drug Metab Dispos; 1980; 8(5):343-8. PubMed ID: 6107233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
    Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
    Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery.
    Cawello W; Braun M; Boekens H
    Drug Metab Dispos; 2009 Oct; 37(10):2055-60. PubMed ID: 19608695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism.
    Maurer G; Schreier E; Delaborde S; Nufer R; Shukla AP
    Eur J Drug Metab Pharmacokinet; 1983; 8(1):51-62. PubMed ID: 6861794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disposition of alpha-[(dimethylamino)methyl]-2-(3-ethyl-5-methyl-4-isoxazolyl)- 1H-indole-3-methanol (59-801), a hypoglycaemic agent in rats, dogs and monkeys.
    Tse FL; Orwig B; Jaffe JM
    Xenobiotica; 1987 Jun; 17(6):741-9. PubMed ID: 3630208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics, metabolism and pharmacodynamics of a benzimidazole angiotensin II type 1 receptor antagonist in the beagle dog and cynomologus monkey.
    Kakiki M; Ishihara H
    Xenobiotica; 1998 Jan; 28(1):77-91. PubMed ID: 9493321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of proterguride in rat and cynomolgus monkey.
    Krause W; Hümpel M
    Xenobiotica; 1988 Jan; 18(1):41-8. PubMed ID: 3354231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.